Evidence map›Paper›PMID 21521749›Full record

ArticleEndocrinology2011

Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary.

M Victoria Recouvreux, M Clara Guida, Daniel B Rifkin, Damasia Becu-Villalobos, Graciela Díaz-Torga

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

M Victoria RecouvreuxInstituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina.
M Clara Guida
Daniel B Rifkin
Damasia Becu-Villalobos
Graciela Díaz-Torga
Consejo Nacional de Investigaciones Científicas y Técnicas · ARExperimental Medicine and Biology Institute · ARNew York University · US

Funding

Regulation of TGF-Beta Activity in the Lung by LTBP-4R01CA034282 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RIFKIN, DANIEL B · 1985 to 2016
$5.8M
NCI NIH HHS R01 CA034282NCI NIH HHS R01CA034282-25
6 · The paper itself

Abstract

Dopamine, acting through the dopamine type 2 receptor (Drd2), is the main inhibitor of pituitary prolactin (PRL) secretion and lactotroph proliferation. TGF-β1 is involved, at least in part, in mediating these actions. It was described that TGF-β1 synthesis in rat pituitary lactotrophs is up-regulated by dopamine and down-regulated by estradiol. TGF-β1 is secreted as a large latent complex. The local regulation of cytokine activation in the pituitary has not yet been explored. In this work, we studied pituitary active and total TGF-β1 content, as well as TGF-β1 mRNA, and the in vivo role of dopamine and estradiol on pituitary TGF-β1 levels. Adult female mice (wild type), and female mice with a null mutation in the Drd2 (Drd2(-/-)), were used. The loss of dopaminergic tone induced a decrease in TGF-β1 mRNA expression, in active and total cytokine content, and in TGF-β type II receptor expression. Dopamine regulation of pituitary TGF-β1 activation process was inferred by the inhibition of active cytokine by in vivo sulpiride treatment. Interestingly, in the absence of dopaminergic tone, estradiol induced a strong increase in active TGF-β1. PRL secretion correlated with active, but not total cytokine. TGF-β1 inhibitory action on lactotroph proliferation and PRL secretion was decreased in Drd2(-/-) pituitary cells, in correlation with decreased TGF-β type II receptor. The study of the TGF-β1 activation process and its regulation is essential to understand the cytokine activity. As an intermediary of dopamine inhibition of lactotroph function, TGF-β1 and local activators may be important targets in the treatment of dopamine agonist-resistant prolactinomas.

Indexed as

AnimalsCell ProliferationCells, CulturedDopamine AgonistsDopamine AntagonistsDopamine D2 Receptor AntagonistsEstradiolFemaleGene Expression RegulationHyperprolactinemiaLactotrophsMiceMice, 129 StrainMice, Inbred C57BLMice, TransgenicPituitary Gland, AnteriorDopamine AgonistsDopamine AntagonistsDopamine D2 Receptor AntagonistsEstradiolProlactinProtein Serine-Threonine KinasesReceptors, Dopamine D2Receptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IIRNA, MessengerTgfb1 protein, mouseTransforming Growth Factor beta1

Identifiers

PMID21521749
PMCPMC3115611
OpenAlexW1969847651

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.